RT Journal Article
SR Electronic
T1 The potential impact of <em>Anopheles stephensi</em> establishment on the transmission of <em>Plasmodium falciparum</em> in Ethiopia and prospective control measures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.19.21262272
DO 10.1101/2021.08.19.21262272
A1 Hamlet, Arran
A1 Dengela, Dereje
A1 Tongren, J. Eric
A1 Tadesse, Fitsum G
A1 Bousema, Teun
A1 Sinka, Marianne
A1 Seyoum, Aklilu
A1 Irish, Seth R.
A1 Armistead, Jennifer S.
A1 Churcher, Thomas
YR 2021
UL http://medrxiv.org/content/early/2021/08/25/2021.08.19.21262272.abstract
AB Anopheles stephensi, the primary urban malaria vector in Asia, was first detected in Africa during 2012 in Djibouti and was subsequently identified in Ethiopia in 2016, and later in Sudan and Somalia. In Djibouti, malaria cases have increased 30-fold from 2012 to 2019 though the impact in the wider region remains unclear.A mechanistic model of malaria transmission was used to estimate the increase in vector density required to explain the trends in malaria cases seen in Djibouti. Applying this vector density to Ethiopia, we assess the potential impact of An. stephensi establishment on Plasmodium falciparum transmission, accounting for pre-existing transmission and control interventions.We estimate that annual P. falciparum malaria cases could increase by 50% (95% CI 14-90) if no additional interventions are implemented. Substantial heterogeneity across the country is predicted and large increases in vector control interventions could be needed to prevent a major public health emergency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding support from the United States Presidents Malaria Initiative and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1). The MRC Centre for Global Infectious Disease Analysis is jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth &amp; Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union; and acknowledges funding by Community Jameel. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Presidents Malaria Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code required to run the analyses are found at https://github.com/arranhamlet/stephensi_ETH_publication https://github.com/arranhamlet/stephensi_ETH_publication